

# Ying Jian Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810427/publications.pdf>

Version: 2024-02-01

60  
papers

1,317  
citations

394421

19  
h-index

377865

34  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2372  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tungsten Oxide Nanorods: An Efficient Nanoplatform for Tumor CT Imaging and Photothermal Therapy. <i>Scientific Reports</i> , 2014, 4, 3653.	3.3	160
2	Graphene oxide-BaGdF <sub>5</sub> nanocomposites for multi-modal imaging and photothermal therapy. <i>Biomaterials</i> , 2015, 42, 66-77.	11.4	140
3	Tumor Angiogenesis Targeted Radiosensitization Therapy Using Gold Nanoprobes Guided by MRI/SPECT Imaging. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 1718-1732.	8.0	67
4	MR/SPECT Imaging Guided Photothermal Therapy of Tumor-Targeting Fe@Fe <sub>3</sub> O <sub>4</sub> Nanoparticles <i>in Vivo</i> with Low Mononuclear Phagocyte Uptake. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 19872-19882.	8.0	59
5	Pretreatment 18F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma—a retrospective study. <i>Radiation Oncology</i> , 2015, 10, 4.	2.7	55
6	Hydrophilic Cu <sub>3</sub> BiS <sub>3</sub> Nanoparticles for Computed Tomography Imaging and Photothermal Therapy. <i>Particle and Particle Systems Characterization</i> , 2015, 32, 668-679.	2.3	51
7	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. <i>Clinical Cancer Research</i> , 2020, 26, 4551-4558.	7.0	49
8	99m Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. <i>Nuclear Medicine and Biology</i> , 2017, 48, 69-75.	0.6	38
9	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1603-1610.	7.0	37
10	The Preliminary Study of 16β-[18F]fluoroestradiol PET/CT in Assisting the Individualized Treatment Decisions of Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0116341.	2.5	36
11	Can Positron Emission Tomography/Computed Tomography with the Dual Tracers Fluorine-18 Fluoroestradiol and Fluorodeoxyglucose Predict Neoadjuvant Chemotherapy Response of Breast Cancer? —A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e78192.	2.5	34
12	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3658-3672.	7.0	31
13	A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. <i>Scientific Reports</i> , 2017, 7, 6584.	3.3	30
14	18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT. <i>Oncologist</i> , 2019, 24, e1277-e1285.	3.7	30
15	Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1538-1549.	6.4	30
16	Textural features of 18F-FDG PET after two cycles of neoadjuvant chemotherapy can predict pCR in patients with locally advanced breast cancer. <i>Annals of Nuclear Medicine</i> , 2017, 31, 544-552.	2.2	27
17	Mesoporous Bi-Containing Radiosensitizer Loading with DOX to Repolarize Tumor-Associated Macrophages and Elicit Immunogenic Tumor Cell Death to Inhibit Tumor Progression. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 31225-31234.	8.0	24
18	18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. <i>Oncotarget</i> , 2015, 6, 29388-29395.	1.8	24

#	ARTICLE	IF	CITATIONS
19	Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. <i>Clinical Imaging</i> , 2014, 38, 470-474.	1.5	23
20	The Predictive Value of Early Changes in 18F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2020, 25, 927-936.	3.7	20
21	Development of High-Resolution Dedicated PET-Based Radiomics Machine Learning Model to Predict Axillary Lymph Node Status in Early-Stage Breast Cancer. <i>Cancers</i> , 2022, 14, 950.	3.7	20
22	Automated synthesis of hypoxia imaging agent [18F]FMISO based upon a modified Explora FDG4 module. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2009, 280, 149-155.	1.5	18
23	Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1144-1152.	3.7	18
24	Establishment and validation of a nomogram with intratumoral heterogeneity derived from 18F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2020, 20, 37.	2.6	18
25	Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0159916.	2.5	18
26	Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis. <i>Journal of Bone Oncology</i> , 2019, 15, 100219.	2.4	17
27	Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2 <sup>+</sup> Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study. <i>Scientific Reports</i> , 2018, 8, 14458.	3.3	16
28	Evaluation of Radiation dosimetry of <sup>99m</sup> Tc-HYNIC-PSMA and imaging in prostate cancer. <i>Scientific Reports</i> , 2020, 10, 4179.	3.3	15
29	The clinical value of 18F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3956-3965.	2.0	14
30	Adding Maximum Standard Uptake Value of Primary Lesion and Lymph Nodes in 18F-Fluorodeoxyglucose PET Helps Predict Distant Metastasis in Patients with Nasopharyngeal Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103153.	2.5	12
31	[ <sup>99m</sup> Tc]Tc-duramycin, a potential molecular probe for early prediction of tumor response after chemotherapy. <i>Nuclear Medicine and Biology</i> , 2018, 66, 18-25.	0.6	12
32	Dual Tracers of <sup>16</sup> α-[18F]fluoro-17 <sup>β</sup> -Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580277.	2.8	12
33	Diagnostic classification of solitary pulmonary nodules using support vector machine model based on 2-[18F]fluoro-2-deoxy-D-glucose PET/computed tomography texture features. <i>Nuclear Medicine Communications</i> , 2020, 41, 560-566.	1.1	12
34	The preclinical study of predicting radiosensitivity in human nasopharyngeal carcinoma xenografts by 18F-ML-10 animal- PET/CT imaging. <i>Oncotarget</i> , 2016, 7, 20743-20752.	1.8	10
35	Relationship between PSA kinetics and Tc <sup>99m</sup> HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. <i>Prostate</i> , 2018, 78, 1215-1221.	2.3	9
36	Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics. <i>Advanced Healthcare Materials</i> , 2018, 7, e1800296.	7.6	9

#	ARTICLE	IF	CITATIONS
37	Clinical value of [18F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer. <i>Clinical Imaging</i> , 2014, 38, 797-801.	1.5	8
38	<sup>99m</sup> Tc-labeled and gadolinium-chelated transferrin enhances the sensitivity and specificity of dual-modality SPECT/MR imaging of breast cancer. <i>RSC Advances</i> , 2016, 6, 20532-20541.	3.6	8
39	Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 834-842.	2.2	8
40	Clinical application of <sup>99m</sup> Tc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2018, 32, 446-452.	2.2	7
41	A novel, chelator-free method for <sup>64</sup> Cu labeling of dendrimers. <i>Journal of Nanoparticle Research</i> , 2018, 20, 1.	1.9	7
42	Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal <sup>18</sup> F-FES PET/CT. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-8.	0.8	7
43	Predictive Value of [18F]ML-10 PET/CT in Early Response Evaluation of Combination Radiotherapy with Cetuximab on Nasopharyngeal Carcinoma. <i>Molecular Imaging and Biology</i> , 2019, 21, 538-548.	2.6	7
44	<sup>18</sup> F-FLT PET/CT imaging for early monitoring response to CDK4/6 inhibitor therapy in triple negative breast cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 600-607.	2.2	7
45	Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1797-1809.	1.8	7
46	Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. <i>BMC Cancer</i> , 2020, 20, 639.	2.6	6
47	Virtual experience™ as an intervention before a positron emission tomography/CT scan may ease patients' anxiety and improve image quality. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 641-648.	1.8	5
48	High specific activity is not optimal: <sup>18</sup> F-fluoroestradiol positron emission tomography-computed tomography results in a breast cancer xenograft. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 576-581.	1.0	4
49	Long-acting octreotide treatment has no impact on tumor uptake of <sup>99m</sup> Tc-HYNIC-TOC in patients with neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2019, 40, 1005-1010.	1.1	4
50	Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using <sup>99m</sup> Tc-duramycin imaging. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109947.	5.6	4
51	Combination of <sup>99m</sup> Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 2191-2199.	1.9	4
52	Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a PET biopsy method. <i>Cancer Management and Research</i> , 2019, Volume 11, 6019-6027.	1.9	3
53	Volumetric parameters derived from FLT-PET performed at completion of treatment predict efficacy of Carbon-ion Radiotherapy in patients with locally recurrent Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 7073-7080.	2.5	3
54	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 3278-3286.	2.8	3

#	ARTICLE	IF	CITATIONS
55	The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer. <i>Nuclear Medicine Communications</i> , 2020, 41, 280-287.	1.1	3
56	The feasibility of 18F-FES and 18F-FDG microPET/CT for early monitoring the effect of fulvestrant on sensitizing docetaxel by downregulating ER $\alpha$ in ER $\alpha$ ++ breast cancer. <i>Annals of Nuclear Medicine</i> , 2018, 32, 272-280.	2.2	2
57	Characterization of heterogeneity of hypoxia with 18FMISO PET/CT, BOLD fMRI and immunohistochemistry in human breast tumor xenograft: initial study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, , .	0.7	1
58	Study of radioimmunoimaging with monoclonal antibody against the patients with SCLC. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 1991, 3, 56-57.	2.2	0
59	The quantitative carbohydrate ingestion ratio for extensive skeletal muscle uptake in 18F-FDG PET/computed tomography. <i>Nuclear Medicine Communications</i> , 2019, 40, 927-932.	1.1	0
60	18F-FDG PET/CT metabolic parameters and HER2 expression in colorectal cancer. <i>Neoplasma</i> , 2021, 68, 875-881.	1.6	0